Drugs / mRNA-2752
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02872025 | Dec 2016 → Mar 2026 overdue | ductal breast carcinoma in situ | Laura Esserman | Active not recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03739931 | Nov 2018 → Aug 2025 | hematopoietic and lymphoid cell neoplasm | ModernaTX, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-2752 | “mRNA-2752 (a combination of interleukin [IL]-23, IL-36γ, and OX40L mRNAs), dose ranging from 1 mg to 4 mg, delivered intratumorally, with 2 to 4 doses given 2 to 3 weeks apart.” PMID 39821301 ↗ Mar 2025 |
| Modality | Messenger RNA (mRNA) | “mRNA-2752 (a combination of interleukin [IL]-23, IL-36γ, and OX40L mRNAs)” PMID 39821301 ↗ Mar 2025 |
| Route | Other | “Injected intralesionally” NCT02872025 ↗ |